SAGE-324

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Chemical compound

Pharmaceutical compound

SAGE-324
Clinical data

Other names	BIIB124
Legal status
Legal status	Investigational
Identifiers
IUPAC name 1-[(3R,5S,8R,9R,10S,13S,14S,17S)-3-Hydroxy-3-(methoxymethyl)-13-methyl-2,4,5,6,7,8,9,10,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2-(5-methyltetrazol-2-yl)ethanone
CAS Number	1832596-09-4
PubChem CID	118548467
Chemical and physical data
Formula	C₂₄H₃₈N₄O₃
Molar mass	430.593 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NN(N=N1)CC(=O)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3CC[C@@H]5[C@@H]4CC[C@@](C5)(COC)O)C
InChI InChI=1S/C24H38N4O3/c1-15-25-27-28(26-15)13-22(29)21-7-6-20-19-5-4-16-12-24(30,14-31-3)11-9-17(16)18(19)8-10-23(20,21)2/h16-21,30H,4-14H2,1-3H3/t16-,17-,18+,19+,20-,21+,23-,24+/m0/s1 Key:QILSKKMYIGWGLH-YRTSKKSESA-N

SAGE-324, also known as BIIB124, is an experimental drug. It is a neurosteroid that works as a GABA_A receptor positive allosteric modulator.^[1]^[2]^[3]

SAGE-324 was being developed by Biogen for the treatment of essential tremor.^[4] Its development was discontinued in 2024 due to lack of efficacy in Phase 2 clinical trials.^[5]

References

^ Cerne, Rok; Lippa, Arnold; Poe, Michael M.; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Golani, Lalit K.; Cook, James M.; Witkin, Jeffrey M. (June 2022). "GABAkines – Advances in the discovery, development, and commercialization of positive allosteric modulators of GABAA receptors". Pharmacology & Therapeutics. 234: 108035. doi:10.1016/j.pharmthera.2021.108035 . PMC 9787737 .
^ Witkin, Jeffrey M.; Lippa, Arnold; Smith, Jodi L.; Jin, Xiaoming; Ping, Xingjie; Biggerstaff, Andrew; Kivell, Bronwyn M.; Knutson, Daniel E.; Sharmin, Dishary; Pandey, Kamal P.; Mian, Md Yeunus; Cook, James M.; Cerne, Rok (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology Biochemistry and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID 35041859. S2CID 245963990.
^ Quagliato, Laiana A.; Carta, Mauro G.; Nardi, Antonio E. (September 2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID 36099401. S2CID 252219658.
^ Ondo, William (1 January 2022). "Chapter Eleven - Enhancing GABA inhibition is the next generation of medications for essential tremor". International Review of Neurobiology. Vol. 163. Academic Press. pp. 317–334. doi:10.1016/bs.irn.202202007. ISBN 9780323899741. PMID 35750368. S2CID 250022192.
^ "Sage Therapeutics and Biogen Announce Topline Results from Phase 2 KINETIC 2 Study of SAGE-324 (BIIB124) for the Treatment of Essential Tremor". Biogen (Press release). 2024年07月24日. Retrieved 2024年07月24日.

Retrieved from "https://en.wikipedia.org/w/index.php?title=SAGE-324&oldid=1236388254"